09:04 AM EDT, 03/10/2025 (MT Newswires) -- Sernova Biotherapeutics (SVA.TO) said Monday that it appointed Pericles Calias as chief development officer and head of research and development.

The regenerative medicine company said Calias brings over two decades of global operational experience in drug product development.

"His deep expertise in leading all aspects of drug product and cell line development is invaluable to Sernova ( SEOVF ) and will add momentum to advancing our Cell Pouch Bio-hybrid Organ as a much-needed functional cure for T1D in collaboration with Evotec," CEO Jonathan Rigby said.

Prior to joining Sernova ( SEOVF ), Calias held leadership roles at life sciences companies including Revolo Biotherapeutics, Cerecor, Sucampo Pharmaceuticals and Shire HGT, according to Sernova ( SEOVF ).

Sernova's ( SEOVF ) shares closed 2.6% lower on Friday to $0.19 on the TSX.